NVIDIA unveils the open-source BioNeMo Framework to enhance drug discovery and molecule design in biopharma through AI tools.
Quiver AI Summary
NVIDIA has announced that its open-source BioNeMo Framework is being widely adopted by leaders in the pharmaceutical and techbio sectors to enhance drug discovery and molecular design. This framework offers tools for researchers to develop specialized biomolecular models and datasets, promoting faster therapeutic design. NVIDIA's vice president of healthcare, Kimberly Powell, highlighted the potential of AI and accelerated computing in pharma, especially following recent Nobel Prize achievements. The BioNeMo platform accelerates AI model creation and deployment while significantly reducing costs and increasing workflow efficiency. Key features include optimized NIM microservices and customizable BioNeMo Blueprints for various applications, enabling research institutions and biotech companies to rapidly integrate AI into their drug discovery processes.
Potential Positives
- NVIDIA's BioNeMo Framework is gaining significant adoption among leading pharmaceutical and techbio companies and academic institutions, highlighting its importance in advancing drug discovery.
- The introduction of the next-generation BioNeMo platform enables accelerated AI model creation and reduces costs, creating a competitive advantage in the biopharma market.
- Over 200 techbios, large pharmaceutical companies, and startups are integrating BioNeMo into their drug discovery workflows, indicating strong market demand and validation of the technology.
- Collaborations with global system integrators and cloud service providers like Accenture, AWS, and Deloitte enhance NVIDIA's reach and potential growth in enterprise adoption.
Potential Negatives
- Forward-looking statements about the NVIDIA BioNeMo Framework's benefits and impact are accompanied by significant risks and uncertainties, suggesting that the anticipated outcomes may not be realized.
- The reliance on third parties for manufacturing, assembly, and testing presents risks that could negatively affect product availability and performance.
- Potential changes in global economic conditions and competition in technological development may adversely impact market acceptance of NVIDIA's products and offerings.
FAQ
What is the NVIDIA BioNeMo Framework?
The NVIDIA BioNeMo Framework is an open-source platform designed to accelerate drug discovery and molecular design through AI models and datasets.
How does BioNeMo improve drug discovery?
BioNeMo enhances drug discovery by offering specialized tools that allow researchers to scale and expedite the creation of biomolecular models.
Who is adopting the BioNeMo Framework?
Leading biotech companies, academic pioneers, and AI researchers globally are adopting the BioNeMo Framework to advance therapeutics development.
What are NVIDIA NIM microservices?
NVIDIA NIM microservices are optimized tools for secure, scalable AI inference, which can be rapidly deployed across various environments.
What benefits do BioNeMo Blueprints provide?
BioNeMo Blueprints offer customizable reference workflows, enabling faster and more cost-effective drug discovery processes for enterprises.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NVDA Congressional Stock Trading
Members of Congress have traded $NVDA stock 23 times in the past 6 months. Of those trades, 13 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $NVDA stock by members of Congress over the last 6 months:
- REPRESENTATIVE PETE SESSIONS has traded it 4 times. They made 3 purchases worth up to $45,000 on 11/01, 09/16, 09/10 and 1 sale worth up to $100,000 on 05/21.
- REPRESENTATIVE THOMAS R. SUOZZI has traded it 3 times. They made 1 purchase worth up to $50,000 on 10/24 and 2 sales worth up to $65,000 on 10/24, 10/02.
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 2 times. They made 1 purchase worth up to $15,000 on 06/28 and 1 sale worth up to $15,000 on 10/17.
- REPRESENTATIVE JOHN JAMES sold up to $15,000 on 09/04.
- REPRESENTATIVE MARJORIE TAYLOR GREENE has traded it 2 times. They made 2 purchases worth up to $30,000 on 09/03, 08/21 and 0 sales.
- REPRESENTATIVE NANCY PELOSI has traded it 2 times. They made 2 purchases worth up to $10,000,000 on 07/26, 06/26 and 0 sales.
- REPRESENTATIVE JARED MOSKOWITZ has traded it 2 times. They made 2 purchases worth up to $30,000 on 07/05 and 0 sales.
- REPRESENTATIVE KATHY E. MANNING has traded it 3 times. They made 0 purchases and 3 sales worth up to $80,000 on 07/02.
- REPRESENTATIVE GREG LANDSMAN has traded it 2 times. They made 0 purchases and 2 sales worth up to $65,000 on 06/03, 05/29.
- REPRESENTATIVE MORGAN MCGARVEY purchased up to $15,000 on 05/31.
- REPRESENTATIVE STEPHEN F. LYNCH purchased up to $15,000 on 05/22.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$NVDA Insider Trading Activity
$NVDA insiders have traded $NVDA stock on the open market 517 times in the past 6 months. Of those trades, 0 have been purchases and 517 have been sales.
Here’s a breakdown of recent trading of $NVDA stock by insiders over the last 6 months:
- MARK A STEVENS has traded it 18 times. They made 0 purchases and 18 sales, selling 1,948,632 shares.
- COLETTE KRESS (EVP & Chief Financial Officer) has traded it 24 times. They made 0 purchases and 24 sales, selling 366,670 shares.
- DONALD F JR ROBERTSON (Principal Accounting Officer) has traded it 4 times. They made 0 purchases and 4 sales, selling 9,000 shares.
- TENCH COXE has traded it 7 times. They made 0 purchases and 7 sales, selling 2,100,000 shares.
- JEN HSUN HUANG (President and CEO) has traded it 343 times. They made 0 purchases and 343 sales, selling 6,000,000 shares.
- AJAY K PURI (EVP, Worldwide Field Ops) has traded it 5 times. They made 0 purchases and 5 sales, selling 100,110 shares.
- DEBORA SHOQUIST (EVP, Operations) has traded it 78 times. They made 0 purchases and 78 sales, selling 41,140 shares.
- DAWN E HUDSON has traded it 5 times. They made 0 purchases and 5 sales, selling 25,000 shares.
- MICHAEL G MCCAFFERY has traded it 31 times. They made 0 purchases and 31 sales, selling 3,936 shares.
- A BROOKE SEAWELL sold 1,438 shares.
- JOHN DABIRI sold 198 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NVDA Hedge Fund Activity
We have seen 2,424 institutional investors add shares of $NVDA stock to their portfolio, and 1,798 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GQG PARTNERS LLC removed 64,596,211 shares (-85.4%) from their portfolio in Q3 2024
- INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC added 55,859,917 shares (+12898.6%) to their portfolio in Q3 2024
- FMR LLC removed 46,189,661 shares (-4.4%) from their portfolio in Q3 2024
- BANK OF AMERICA CORP /DE/ added 39,169,586 shares (+19.0%) to their portfolio in Q3 2024
- PRICE T ROWE ASSOCIATES INC /MD/ removed 36,974,039 shares (-8.3%) from their portfolio in Q3 2024
- STATE STREET CORP removed 35,750,704 shares (-3.6%) from their portfolio in Q3 2024
- SCHWAB CHARITABLE FUND added 33,945,040 shares (+inf%) to their portfolio in Q2 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
ATLANTA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- SC24 -- NVIDIA today announced that global pharmaceutical and techbio industry leaders, academic pioneers and AI researchers are adopting the open-source NVIDIA® BioNeMo™ Framework to advance drug discovery and accelerate molecule design.
Researchers require specialized biomolecular models and datasets that allow them to gather insights at scale to design therapeutics faster. The open-source BioNeMo Framework offers a collection of accelerated computing tools designed to exponentially scale AI models for biomolecular research, bringing a new level of supercomputing to biopharma.
“The convergence of AI, accelerated computing and expanding datasets offers unprecedented opportunities for the pharmaceutical industry, as evidenced by recent Nobel Prize wins in chemistry,” said Kimberly Powell, vice president of healthcare at NVIDIA. “To help unravel the complexities of biological systems, we’ve introduced the open-source BioNeMo Framework, which will enable researchers worldwide to accelerate the development of life-saving treatments.”
Pioneering biotech companies, techbio researchers and AI platform companies and organizations are already contributing or will contribute to the open-source framework, including A Alpha Bio; Argonne National Laboratory; Dyno Therapeutics; Genentech, a member of the Roche Group; Ginkgo Bioworks; Relation; VantAI and Weights & Biases. Key research leaders known for advancing computational science also use the BioNeMo Framework to drive innovation.
“Argonne has contributed billion-parameter biological models that require specialized software to train across high-performance computing environments,” said Arvind Ramanathan, computational science group leader at Argonne National Laboratory. “With BioNeMo, Argonne and the broader biotech community gain an enterprise-level, open-source solution that enables researchers to easily scale the training of large biological foundation models — in labs that otherwise wouldn’t have the computational expertise to do so.”
Introducing the Next-Generation BioNeMo Platform
The end-to-end NVIDIA BioNeMo platform is designed to accelerate AI model creation, customization and deployment for drug discovery and molecular design. Seamlessly integrated with accelerated computing infrastructure, it reduces costs, increases scale and speeds up drug discovery workflows to provide fast, reliable insights from biomolecular data.
In addition to the BioNeMo Framework, the platform supports NVIDIA NIM ™ — optimized microservices for secure, scalable AI inference — and NVIDIA BioNeMo Blueprints, which are optimized reference designs for wet-lab and computational workflows.
NVIDIA also announced a new collection of optimized, easy-to-use NIM microservices for BioNeMo. The microservices can be deployed quickly and easily on premises or in any data center or cloud. This offers developers the flexibility to run applications across a diverse range of environments and reduces the time from inference to insights for biological drug discovery research.
The newly available NIM microservices support industry-leading models, including:
- AlphaFold2 is a deep learning model, developed by Google DeepMind, designed to transform protein structure prediction. Researchers using the AlphaFold2 NIM microservice for BioNeMo achieved a 5x speedup when predicting protein structures in near real time.
- DiffDock 2.0 is based on MIT research and trained on the gold-standard PLINDER dataset . With the DiffDock 2.0 NIM microservice, researchers were able to predict the orientation of a molecule 6.2x faster and 16% more accurately.
- RFdiffusion and ProteinMPNN NIM microservices help speed up the process of designing novel proteins to bind with a target molecule and enable the creation of new protein therapeutics.
BioNeMo now includes new acceleration libraries, including cuEquivariance, that accelerate the mathematical computations essential to DiffDock predictions for chemistry.
Companies can use NVIDIA BioNeMo Blueprints, a catalog of customizable reference AI workflows, to help developers scale their AI deployments as enterprise-grade production pipelines.
The BioNeMo Blueprint for virtual screening provides a customizable, easy-to-follow workflow for using NIM microservices to design small molecules faster, while saving time and costs.
More than 200 techbios, large pharma and startup users are already integrating BioNeMo into their computer-aided drug discovery platforms and workflows.
Global system integrators, software providers and cloud service providers such as Accenture, AWS and Deloitte are bringing NVIDIA BioNeMo Blueprints to enterprises worldwide.
About NVIDIA
NVIDIA (NASDAQ: NVDA) is the world leader in accelerated computing.
For further information, contact:
Janette Ciborowski
Corporate Communications
NVIDIA Corporation
+1-734-330-8817
jciborowski@nvidia.com
Certain statements in this press release including, but not limited to, statements as to: the benefits, impact, and performance of NVIDIA’s products, services, and technologies, including NVIDIA BioNeMo Framework, NVIDIA NIM, and NVIDIA BioNeMo Blueprints; third parties using or adopting our products and technologies, the benefits and impact thereof, and the features, performance and availability of their offerings; the open-source BioNeMo Framework enabling researchers worldwide to accelerate the development of life-saving treatments; and pioneering biotech companies, techbio researchers and AI platform companies and organizations contributing to the open-source framework are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic conditions; our reliance on third parties to manufacture, assemble, package and test our products; the impact of technological development and competition; development of new products and technologies or enhancements to our existing product and technologies; market acceptance of our products or our partners' products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of our products or technologies when integrated into systems; as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company's website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
© 2024 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, BioNeMo and NVIDIA NIM are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. Other company and product names may be trademarks of the respective companies with which they are associated. Features, pricing, availability and specifications are subject to change without notice.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1e0417ca-84c4-4cf3-aa18-a5260132bcc5
